The NICE guideline on multimorbidity explains that multimorbidity refers to the presence of 2 or more long-term health conditions, which can include:
defined physical and mental health conditions such as diabetes or schizophrenia
ongoing conditions such as learning disability
symptom complexes such as frailty or chronic pain
sensory impairment such as sight or hearing loss
alcohol and substance misuse.
The guideline notes that multimorbidity is common, becomes more common as people age, and is more common in people from less affluent areas. In older people, multimorbidity is largely because of higher rates of physical health conditions, whereas in younger people and people from less affluent areas, it is often because of a combination of physical and mental health conditions (notably depression).
Multimorbidity is associated with reduced quality of life, higher mortality, polypharmacy and high treatment burden, higher rates of adverse drug events, and much greater health services use (including unplanned or emergency care). A particular issue for health services and healthcare professionals is that treatment regimens (including non-pharmacological treatments) can easily become very burdensome for people with multimorbidity, and care can become uncoordinated and fragmented.
The NICE guideline on multimorbidity recommends considering an approach to care that takes account of multimorbidity in circumstances outlined in the guideline. This approach to care involves personalised assessment and the development of an individualised management plan. The aim should be to improve quality of life by reducing treatment burden, adverse events, and unplanned or uncoordinated care. The approach takes account of the person's individual needs, preferences for treatments, health priorities and lifestyle. It aims to improve coordination of care across services, particularly if this has become fragmented. Medicines are likely to be just one aspect of a person's care and should not be considered in isolation.
The guideline has recommendations on how to identify adults with multimorbidity who are at risk of adverse events, and how to assess frailty. Guidance and resources to support the GP core contract (2017/18) regarding frailty (updated April 2019) are available on the NHS England website. The British Medical Association has also published advice for clinicians on identifying and helping people with frailty.
The NICE quality standard on multimorbidity describes a concise set of prioritised statements designed to drive measurable quality improvements within this area.
Polypharmacy in people with multimorbidity is often driven by the introduction of multiple medicines intended to reduce the risk of future morbidity and mortality in specific health conditions. However, the evidence for recommendations in NICE guidance on single health conditions is often drawn from people without multimorbidity who are participating in studies and who are taking fewer regular medicines. The absolute benefit made by each additional medicine is likely to reduce when a person is taking multiple preventative medicines; often referred to as the 'law of diminishing returns'. Conversely, the risk of harms is likely to increase the more medicines a person takes. The King's Fund report (2013), All Wales Medicines Strategy Group (AWMSG) guidance (2014) and NHS Scotland guidance (2018) on polypharmacy recognise that not all polypharmacy is inappropriate. The King's Fund proposed a classification where treatment with multiple medicines may be either 'appropriate' or 'problematic':
Prescribing for a person for complex conditions or for multiple conditions in circumstances where medicines use has been optimised and where the medicines are prescribed according to best evidence.
The prescribing of multiple medicines inappropriately, or where the intended benefits from the medicines are not realised.
Problematic polypharmacy may arise if medicines are used without a good evidence base for doing so, or if (taking into account the person's views and preferences) the risk of harm from treatments is likely to outweigh the benefits, or where 1 or more of the following apply:
the medicine combination is hazardous because of interactions
the overall demands of medicine-taking, or 'pill burden', are unacceptable to the person
these demands make it difficult to achieve clinically useful medicines adherence
medicines are being prescribed to treat the side effects of other medicines, but alternative solutions are available to reduce the number of medicines prescribed.
In December 2018, the Department of Health and Social Care announced that a review into overprescribing in the NHS will take place. The review will look at addressing problematic polypharmacy, creating a more efficient handover between primary and secondary care, improving management of non-reviewed repeat prescriptions, the role of digital technologies in reducing overprescribing, and the increased role for other forms of care, including social prescribing.
The World Health Organisation (WHO) Third Global Patient Safety Challenge, Medication without harm, has included the appropriate management of polypharmacy as a key flagship area to address. The aim is to reduce severe, avoidable, medication-related harm by 50% over 5 years, globally. NHS Improvement has established the Medicines Safety Programme. This is gathering opinion about the most important priorities to address, through 3 lenses:
high risk drugs
high risk parts of the medicines use process
patients with the highest vulnerabilities
The risks associated with medicines with anticholinergic effects in polypharmacy are highlighted in polypharmacy resources such as NHS Scotland guidance (2018) and All Wales Medicines Strategy Group (AWMSG) guidance (2014). A systematic review and meta-analysis (Ruxton et al. 2015) reported that use of such medicines was associated with an increased risk of cognitive impairment and all-cause mortality in older people, and some medicines were associated with an increased risk of falls. This is discussed further in NICE's eyes on evidence commentary on drugs with anticholinergic effects and risk of cognitive impairment, falls and all-cause mortality.
More specifically, the NICE guideline on dementia published in 2018 notes the risk of cognitive impairment associated with an increased anticholinergic burden. It recommends that health professionals should consider minimising the use of medicines associated with increased anticholinergic burden, and if possible look for alternatives:
when assessing whether to refer a person with suspected dementia for diagnosis
during medication reviews with people living with dementia.
The guideline states that, although there are validated tools for assessing anticholinergic burden (for example, the Anticholinergic Cognitive Burden Scale), there is insufficient evidence to recommend one over the others.
A large, nested, case-control study in UK general practices found that some classes of anticholinergic medicines were significantly associated with an increase in incidence of dementia. This is discussed further in NICE's medicines evidence commentary on anticholinergic medicines and the risk of dementia.
Other medicines optimisation: key therapeutic topics discuss the risks associated with medicines, see especially:
NICE guidelines should be understood as 'guidelines, not tramlines': every guideline states clearly that although healthcare professionals are expected to take it fully into account when exercising their judgement, they should do so alongside the individual needs, preferences and values of their patients or service users. The NICE guideline on medicines optimisation recommends that all people are offered the opportunity to be involved in making decisions about their medicines. The NICE guideline on patient experience in adult NHS services recommends holding discussions in a way that encourages the patient to express their personal needs and preferences for care, treatment, management and self-management. This is known as shared decision making, and is discussed fully in another NICE key therapeutic topic on shared decision making.
The NICE guideline on multimorbidity recommends that healthcare professionals should think carefully about the risks and benefits of individual treatments recommended in guidance for single health conditions. These should be discussed with the person alongside their preferences for care and treatment. The guideline also recommends using a tailored approach to care that takes account of multimorbidity for people of any age who are prescribed 15 or more regular medicines, and that this approach is considered for people of any age who:
are prescribed 10 to 14 regular medicines
are prescribed fewer than 10 regular medicines but are at particular risk of adverse events.
The NICE guideline on medicines optimisation recognises that optimising a person's medicines can support the management of long-term health conditions, multimorbidity and polypharmacy. Deprescribing is the complex process needed to ensure the safe and effective withdrawal of inappropriate medicines (A patient-centred approach to polypharmacy, NHS Specialist Pharmacy Service 2017). Resources have been developed to support healthcare professionals who are reviewing people with polypharmacy to help guide decision making about the appropriateness of prescribing and deprescribing (see table 1). These resources include the Royal Pharmaceutical Society guidance on polypharmacy: getting our medicines right, case examples and practical tools, such as the STOPP/START and NO TEARS tools. The NICE guideline on multimorbidity recommends that the use of a screening tool is considered (for example, the STOPP/START tool in older people) to identify medicine-related safety concerns and medicines the person might benefit from but is not currently taking. Several published examples highlight the importance of identifying underuse and overuse of medicines. For more information see, NICE's medicines evidence commentaries on:
The scope for the NICE guideline on multimorbidity included reviewing evidence for the effect of stopping drugs. However, although the NICE guideline development group was able to make recommendations about stopping bisphosphonates, there was insufficient evidence about stopping other treatments (such as statins and antihypertensives). A number of resources are available to help healthcare professionals approach the challenges of inappropriate polypharmacy, see table 1.
Bruyère Research Institute Deprescribing Guidelines Research Team has produced a benzodiazepine and Z-drug deprescribing algorithm that supports recommendations in the NICE guidance on the use of zolpidem and zopiclone for the short-term management of insomnia, and medicines optimisation.
Addressing inappropriate polypharmacy is a medicines optimisation priority that is supported by the work of the Regional Medicines Optimisation Committees.
The NICE quality standard on medicines optimisation describes a concise set of prioritised statements designed to drive measurable quality improvements within this area.
Primary Care Commissioning has published a collection of case studies from the clinical pharmacists in general practice programme, illustrating the benefits gained by some of the nearly 600 practices taking part. An independent evaluation of the pilot scheme was undertaken by researchers from the University of Nottingham supported by patient representatives and colleagues from the University of Queensland, Australia. The evaluation showed that pharmacists increase capacity in patient appointments either through direct face-to-face contact or releasing GP time by taking on tasks ordinarily done by GPs. Pharmacists provided numerous examples of interventions to optimise patient's medicines and promote safer prescribing.
The Specialist Pharmacy Service WHO good practice repository has been created to support the NHS Medicines Safety Programme. Examples of good practice are categorised against each of the WHO's suggested work domains including Medication Without Harm. The English Deprescribing Network also shares ideas, best practice and learning, to potentially shape policy and drive change across organisations.
There are several NICE shared learning case studies relating to multimorbidity and polypharmacy, showing how NICE guidance and standards have been put into practice by some NHS organisations: